Ruth E. Abrams

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma

Ruth E. Abrams, Kamau Pierre, Nizar El-Murr, Edward Seung et autres

In relapsed and refractory multiple myeloma (RRMM), there are few treatment options once patients progress from the established standard of care. Several bispecific T-cell engagers (TCE) are in clinical development for multiple myeloma (MM), designed to promote T-cell activation and tumor killing …

us, fr (code pays fourni par la source)

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat

Ruth E. Abrams, Chanchala Kaddi, Mengdi Tao, Randolph J. Leiser et autres

Gaucher's disease type 1 (GD1) leads to significant morbidity and mortality through clinical manifestations, such as splenomegaly, hematological complications, and bone disease. Two types of therapies are currently approved for GD1: enzyme replacement therapy (ERT), and substrate reduction therapy (SRT). In this …

us, it (code pays fourni par la source)

Development of an Integrated Human Model of Electrophysiology and Actin-Myosin Binding to Describe Sarcomere Force Generation in Cardiomyocytes

Ruth E. Abrams, Hans-Christoph Schneider, Tatiana Radziun, Britta Goebel et autres

us, de, fr (code pays fourni par la source)

Equilibria for Large Metabolic Systems and the LIFE Approach

Sean T. McQuade, Zheming An, Nathaniel J. Merrill, Ruth E. Abrams et autres

In a recent paper [9] the authors introduced a new methodology for the simulation and control of large metabolic systems called LIFE (Linear-in-Flux-Expressions). In many metabolic networks encountered in Quantitative Systems Pharmacology, the corresponding ODE systems are linear in the fluxes among …

us (code pays fourni par la source)

Integrated quantitative systems pharmacology (QSP) model of lysosomal diseases provides an innovative computational platform to support research and therapeutic development for the sphingolipidoses

Chanchala Kaddi, Federico Reali, Luca Marchetti, Bradley Niesner et autres

us, it (code pays fourni par la source)

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

Jeffrey E. Ming, Ruth E. Abrams, Derek W. Bartlett, Mengdi Tao et autres

Reduction in low-density lipoprotein cholesterol (LDL-C) is associated with decreased risk for cardiovascular disease. Alirocumab, an antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduces LDL-C. Here, we report development of a quantitative systems pharmacology (QSP) model integrating peripheral and liver …

fr, us (code pays fourni par la source)

Linear-In-Flux-Expressions Methodology: Toward a Robust Mathematical Framework for Quantitative Systems Pharmacology Simulators

Sean T. McQuade, Ruth E. Abrams, Jeffrey S. Barrett, Benedetto Piccoli et autres

Quantitative Systems Pharmacology (QSP) modeling is increasingly used as a quantitative tool for advancing mechanistic hypotheses on the mechanism of action of a drug, and its pharmacological effect in relevant disease phenotypes, to enable linking the right drug to the right patient. …

us (code pays fourni par la source)